First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients

Authors :: Jeeyun Lee
Won Ki Kang
Seong-Won Song
Seung Hoon Kim
Jung Ju Kim
Young Suk Park
Ho Yeong Lim
Hukeun Lee
Su Jin Lee
Kyoung-Mee Kim
Joon Oh Park
Se Hoon Park
Jung Yong Kim
Song-Jae Lee
Sung Hong
Jeong-Won Lee
Do-Hyun Nam
Source :: Journal of Clinical Oncology. 36:e14501-e14501
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e14501Background: The aim of this study was to determine the maximum tolerate dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of YYB101, a hepatocyte growth factor (HGF) neutra...

Subjects :: Cancer Research
biology
business.industry
First in human
Oncology
Refractory
Pharmacokinetics
Pharmacodynamics
medicine
Cancer research
biology.protein
Hepatocyte growth factor
Antibody
Solid tumor
business
medicine.drug

Full Text Access

Tools